{
    "root": "6e384a23-a8c4-455a-b84b-847393d491e6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Deferoxamine"
    },
    "value": "20250320",
    "ingredients": [
        {
            "name": "DEFEROXAMINE MESYLATE",
            "code": "V9TKO7EO6K"
        }
    ],
    "indications": "deferoxamine mesylate injection iron-chelating agent indicated : \u2022 adjunct standard measures treatment acute iron intoxication . ( 1.1 ) \u2022 treatment transfusional iron overload patients chronic anemia . ( 1.2 ) limitations deferoxamine mesylate injection indicated treatment primary hemochromatosis ( since phlebotomy method choice removing excess iron disorder ) .",
    "contraindications": "( based body weight mg/kg/day ) , rates , mode adults pediatric patients individually determined adapted course therapy based severity patient 's iron overload . minimum daily dose deferoxamine mesylate injection 20 mg/kg/day adults pediatric patients . maximum daily dose 40 mg/kg/day pediatric patients 60 mg/kg/day adults .",
    "warningsAndPrecautions": null,
    "adverseReactions": "deferoxamine mesylate injection contraindicated patients : \u2022a history hypersensitivity reaction deferoxamine inactive ingredients [ description ( 11 ) ] . included anaphylaxis [ ( 5.1 ) ] . \u2022severe renal disease anuria since iron chelate excreted primarily kidney [ ( 5.3 ) ] .",
    "indications_original": "Deferoxamine Mesylate for Injection is an iron-chelating agent indicated: \u2022 As an adjunct to standard measures for the treatment of acute iron intoxication. ( 1.1 ) \u2022 For the treatment of transfusional iron overload in patients with chronic anemia. ( 1.2 ) Limitations of Use Deferoxamine Mesylate for Injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder).",
    "contraindications_original": "The dosage (based on body weight in mg/kg/day), rates of administration, and mode of administration for both adults and pediatric patients are individually determined and adapted during the course of therapy based on the severity of the patient's iron overload. The minimum daily dose of Deferoxamine Mesylate for Injection is 20 mg/kg/day for both adults and pediatric patients. The maximum daily dose is 40 mg/kg/day for pediatric patients and 60 mg/kg/day for adults.",
    "adverseReactions_original": "Deferoxamine Mesylate for Injection is contraindicated in patients with: \n                  \n                     \n                        \u2022A history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients [see Description (11)]. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)]. \n                     \n                        \u2022Severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney [see Warnings and Precautions (5.3)]."
}